Detalhe da pesquisa
1.
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
N Engl J Med
; 388(8): 694-705, 2023 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36812433
2.
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
N Engl J Med
; 388(8): 706-718, 2023 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36812434
3.
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
N Engl J Med
; 386(11): 1013-1025, 2022 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35294811
4.
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
N Engl J Med
; 383(11): 1018-1027, 2020 09 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32905674
5.
Consistency of serial ultrasonographic joint tissue measurements by the Joint tissueActivity and Damage Exam (JADE) protocol in relation to hemophilic joint health parameters.
BMC Musculoskelet Disord
; 24(1): 299, 2023 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37061676
6.
Diabetes, hepatitis C and human immunodeficiency virus influence hypertension risk differently in cohorts of haemophilia patients, veterans and the general population.
Haemophilia
; 28(6): e228-e236, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35877992
7.
Blood pressure in persons with haemophilia with a focus on haemophilia-specific risk factors.
Haemophilia
; 28(6): 977-985, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35768896
8.
Risk of diabetes in haemophilia patients compared to clinic and non-clinic control cohorts.
Haemophilia
; 28(3): 445-452, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35238443
9.
Quantitative measurements of haemophilic joint tissues by point-of-care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters.
Haemophilia
; 27(5): 866-875, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34171150
10.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Haemophilia
; 27(6): 911-920, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34614267
11.
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Haemophilia
; 27(6): 921-931, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34636112
12.
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Haemophilia
; 26(6): 975-983, 2020 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-33012060
13.
Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophilic Joints.
J Ultrasound Med
; 38(6): 1569-1581, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30371941
14.
Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
Eur J Haematol
; 100 Suppl 1: 14-24, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29498783
15.
Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
Eur J Haematol
; 100 Suppl 1: 5-13, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29498784
16.
A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
Haemophilia
; 28(4): e105-e108, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35510949
17.
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Cancer
; 121(4): 570-9, 2015 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25312684
18.
Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia.
Am J Hematol
; 90 Suppl 2: S17-22, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26619193
19.
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Blood
; 119(13): 3031-7, 2012 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-22223821
20.
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
J Thromb Haemost
; 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38614387